切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2012, Vol. 06 ›› Issue (05) : 484 -493. doi: 10.3877/cma. j. issn.1674-0807.2012.05.002

专家论坛

早期乳腺癌治疗进展荟萃:2012 年ASCO 年会报道
张瑾1   
  1. 1.天津 300060,天津医科大学附属肿瘤医院乳腺三科;教育部乳腺癌防治重点实验室;天津肿瘤防治重点实验室
  • 收稿日期:2012-08-23 出版日期:2012-10-01

Advances in the treatment of early breast cancer: report

Jin ZHANG   

  • Received:2012-08-23 Published:2012-10-01
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张瑾. 早期乳腺癌治疗进展荟萃:2012 年ASCO 年会报道[J/OL]. 中华乳腺病杂志(电子版), 2012, 06(05): 484-493.

Jin ZHANG. Advances in the treatment of early breast cancer: report[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2012, 06(05): 484-493.

表1 糖尿病相关因素与乳腺癌发生的风险相关性[4]
危险因素 累积相关风险 95%置信区间
糖尿病 1.23 1.12～1.34
体力活动 0.88 0.85～0.92
血糖负荷 1.05 1.00～1.10
空腹血糖 1.14 0.94～1.37
血清胰岛素 1.26 0.86～1.84
二甲双胍 0.97 0.82～1.16
长效胰岛素 1.10 0.94～1.30
表2 各化疗方案用药情况[12]
方案 例数 剂量 用药间隔 周期
标准AC序贯P 2 A60mg/m2
C600mg/m2
P80mg/m2		 3周

1周		 4

12
剂量密集型AC序贯P 12 A60mg/m2
C600mg/m2
G-CSF
P80mg/m2
2周

1周
4

12
TAC 1 T75mg/m2
A50mg/m2
C500mg/m2
3周
6
TCa 16 T75mg/m2
C600mg/m2		 3周 4～6
TcarboH 3 T75mg/m2
Carbo AUC6
C#1H8mg/kg
6mg/kg		 3周 6
表3 NSABP B-38 试验无瘤生存率和总生存率
方案 5年DFS P值 5年OS P值
TAC 80.1% 0.71a 89.6% 0.32a
DD AC→P 82.2% 0.27a 89.1% 0.25a
DD AC→PG 80.6% 90.8%
表4 NSABP B-38 试验不同化疗方案的不良反应
不良反应 TAC DD AC→P DD AC→PG
发热性中性粒细胞减少 9% 4% 4%
感觉性神经病变 12% 26% 33%
死亡(例数) 13 5 7
AML/MDS(例数) 5 8 11
[1]
Moskowitz CS, Chou JF, Wolden SL, et al. New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) study[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=100009.
[2]
Chlebowski RT, Anderson GL, Kuller LH, et al. Estrogen plus progestin (E+P) and breast cancer incidence and mortality[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview = abst _ detail _view＆confID=114＆abstractID=99026.
[3]
Bonanni B, Maisonneuve P, Serrano D, et al. A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial[EB/OL].[2012-09-10].http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=97571.
[4]
Boyle P, Boniol M, Koechlin A, et al. Diabetes, related factors, and breast cancer risk[EB/OL]. [2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview= abst_detail_view＆confID=114＆abstractID=97545.
[5]
Balko JM, Sanders M, Kuba MG, et al. A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=98384.
[6]
Yi M, Mittendorf EA, Hwang RF, et al. Are mastectomy rates really increasing? Experiences from a single institution and a population-based database[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=97891.
[7]
Nishimura J, Choi A, Kim S, et al. Trends in the use of breast-conserving surgery and adjuvant radiation therapy in patients with DCIS: A U. S. population-based analysis from 1996 to 2007[EB/OL]. [2012-09-10]. http:/ /www. asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=95529.
[8]
Kapoor NS, Shamonki J, Yoon JL, et al. Is there a need for sentinel lymph node biopsy in microinvasive breast cancer?[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=93812.
[9]
Motomura K, Izumi T, Tateishi S, et al. SPIO-enhanced MR imaging for axillary staging to avoid sentinel node biopsy in patients with breast cancer[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=93505.
[10]
Surapaneni R, Jozefara J, Hendershott K, et al. Breast cancer surgery during pregnancy[EB/OL]. [2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=100745.
[11]
Huo DZ, Hou NQ, Jaskowiak NT, et al. Postmastectomy radiotherapy for patients with one to three positive lymph nodes:Utilization and benefit[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=96879.
[12]
Lawrence LM, Shah A, Young ME, et al. Phase I/II trial of partial breast irradiation (PBI) with various concurrent chemo-therapy regimens[EB/OL].[2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=100778.
[13]
Swain SM, Tang G, Geyer CE, et al. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dosedense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel,doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer[EB/OL]. [2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=98794.
[14]
Migdady Y, Sikov WM, Sakr BJ, et al. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER-2-positive breast cancer[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=91121.
[15]
Martin M, Lluch A, Ruiz A, et al. Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial [EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview = abst _ detail _view＆confID=114＆abstractID=99535.
[16]
Sparano JA, O'Neill A, Gray RJ, et al. 10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN1 and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features[EB/OL].[2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=94749.
[17]
Schneeweiss A, Ruiz A, Manikhas A, et al. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts?＆vmview=abst_detail_view＆confID=114＆abstractID=91799.
[18]
Altwairgi AK, Parulekar W, Chapman JW, et al. Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT)with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27[EB/OL]. [2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=93737.
[19]
Shepherd LE, Chapman JW, Ali SM, et al. Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=93668.
[20]
Gregory W, Marshall H, Bell R, et al. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=100238.
[21]
Ambros TF, Reis IM, Bagga D, et al. Neoadjuvant chemotherapy versus neoadjuvant hormonal therapy in postmenopausal women with ER-positive, HER-2/neu negative locally advanced breast cancer[EB/OL]. [2012-09-10]. http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=94955.
[22]
Robidoux A, Tang G, Rastogi P, et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER-2+operable breast cancer: NSABP protocol B-41[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆abstractID=99368.
[23]
Boyle F, Smith IE, O'Shaughnessy J, et al. Lapatinib in HER-2+ early breast cancer: Quality of life analysis. [EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview = abst _ detail _ view＆confID =114＆abstractID=98735.
[24]
Frenel JS, Rodrigues MJ, Peron J, et al. Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER-2 overexpressing breast carcinomas.[EB/OL].[2012-09-10].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts?＆vmview=abst_detail_view＆confID=114＆abstractID=97503.
[25]
Dang CT, Gianni L, Romieu G, et al. Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early stage HER-2-positive breast cancer[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview = abst _ detail _ view＆confID =114＆abstractID=100949.
[26]
Chae YK, Brown EN, Lei XD, et al. ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy[EB/OL]. [2012-09-10]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? ＆vmview=abst_detail_view＆confID=114＆ abstractID=96713.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号